688302 Stock Overview
A clinical-stage pharmaceutical company, engages in the development and production of therapeutics for cancers and metabolic syndromes. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Hinova Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥27.42 |
| 52 Week High | CN¥50.99 |
| 52 Week Low | CN¥22.60 |
| Beta | 0.0052 |
| 1 Month Change | -22.48% |
| 3 Month Change | -18.20% |
| 1 Year Change | -44.78% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -8.90% |
Recent News & Updates
Shareholder Returns
| 688302 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -8.0% | -3.6% | -4.1% |
| 1Y | -44.8% | -6.0% | 6.9% |
Return vs Industry: 688302 underperformed the CN Pharmaceuticals industry which returned -6% over the past year.
Return vs Market: 688302 underperformed the CN Market which returned 6.9% over the past year.
Price Volatility
| 688302 volatility | |
|---|---|
| 688302 Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in CN Market | 11.6% |
| 10% least volatile stocks in CN Market | 4.9% |
Stable Share Price: 688302 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688302's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 181 | Yuanwei Chen | www.hinovapharma.com |
Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and production of therapeutics for cancers and metabolic syndromes. It develops drugs based on proteolysis targeting chimera and deuteration technology. The company’s products pipeline includes HC-1119, a product in phase III clinical trials with castration resistant prostate cancer indications; HP501, a product in phase II clinical trials for the treatment of hyperuricemia and gout; HP558, a product in phase II clinical trials to treat various late-stage cancers; and HP518, an oral PROTAC drug in phase I clinical trials with a focus on to solve the drug resistance of AR-mutated prostate cancer.
Hinova Pharmaceuticals Inc. Fundamentals Summary
| 688302 fundamental statistics | |
|---|---|
| Market cap | CN¥2.70b |
| Earnings (TTM) | -CN¥210.18m |
| Revenue (TTM) | CN¥109.73k |
Over9,999x
P/S Ratio-12.9x
P/E RatioIs 688302 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688302 income statement (TTM) | |
|---|---|
| Revenue | CN¥109.73k |
| Cost of Revenue | CN¥96.52k |
| Gross Profit | CN¥13.21k |
| Other Expenses | CN¥210.20m |
| Earnings | -CN¥210.18m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 19, 2025
| Earnings per share (EPS) | -2.12 |
| Gross Margin | 12.04% |
| Net Profit Margin | -191,539.74% |
| Debt/Equity Ratio | 0% |
How did 688302 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/09 09:52 |
| End of Day Share Price | 2025/01/09 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hinova Pharmaceuticals Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tielin Chen | Topsperity Securities |
| Xinming Zhou | Topsperity Securities |